United States Musculoskeletal Disorders Drugs Market Report 2017

November 2017 | 102 pages | ID: U3083B842A9EN
QYResearch

Abstracts

In this report, the United States Musculoskeletal Disorders Drugs market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.

Geographically, this report splits the United States market into seven regions:

• The West
• Southwest
• The Middle Atlantic
• New England
• The South
• The Midwest
• with sales (volume), revenue (value), market share and growth rate of Musculoskeletal Disorders Drugs in these regions, from 2012 to 2022 (forecast).

United States Musculoskeletal Disorders Drugs market competition by top manufacturers/players, with Musculoskeletal Disorders Drugs sales volume, price, revenue (Million USD) and market share for each manufacturer/player; the top players including

• AbbVie
• Amgen
• Johnson & Johnson
• F. Hoffmann-La Roche Ltd
• Pfizer Inc
• Eli Lilly

On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into

• Rheumatoid Arthritis
• Muscle Relaxants
• Others

On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate for each application, including

• Rheumatoid Arthritis
• Osteoarthritis
• Osteoporosis
• Psoriatic Arthritis
• Ankylosing Spondylitis
• Others

If you have any special requirements, please let us know and we will offer you the report as you want.

Contents

United States Musculoskeletal Disorders Drugs Market Report 2017

1 MUSCULOSKELETAL DISORDERS DRUGS OVERVIEW

1.1 Product Overview and Scope of Musculoskeletal Disorders Drugs
1.2 Classification of Musculoskeletal Disorders Drugs by Product Category
  1.2.1 United States Musculoskeletal Disorders Drugs Market Size (Sales Volume) Comparison by Type (2012-2022)
  1.2.2 United States Musculoskeletal Disorders Drugs Market Size (Sales Volume) Market Share by Type (Product Category) in 2016
  1.2.3 Rheumatoid Arthritis
  1.2.4 Muscle Relaxants
  1.2.5 Others
1.3 United States Musculoskeletal Disorders Drugs Market by Application/End Users
  1.3.1 United States Musculoskeletal Disorders Drugs Market Size (Consumption) and Market Share Comparison by Application (2012-2022)
  1.3.2 Rheumatoid Arthritis
  1.3.3 Osteoarthritis
  1.3.4 Osteoporosis
  1.3.5 Psoriatic Arthritis
  1.3.6 Ankylosing Spondylitis
  1.3.7 Others
1.4 United States Musculoskeletal Disorders Drugs Market by Region
  1.4.1 United States Musculoskeletal Disorders Drugs Market Size (Value) Comparison by Region (2012-2022)
  1.4.2 The West Musculoskeletal Disorders Drugs Status and Prospect (2012-2022)
  1.4.3 Southwest Musculoskeletal Disorders Drugs Status and Prospect (2012-2022)
  1.4.4 The Middle Atlantic Musculoskeletal Disorders Drugs Status and Prospect (2012-2022)
  1.4.5 New England Musculoskeletal Disorders Drugs Status and Prospect (2012-2022)
  1.4.6 The South Musculoskeletal Disorders Drugs Status and Prospect (2012-2022)
  1.4.7 The Midwest Musculoskeletal Disorders Drugs Status and Prospect (2012-2022)
1.5 United States Market Size (Value and Volume) of Musculoskeletal Disorders Drugs (2012-2022)
  1.5.1 United States Musculoskeletal Disorders Drugs Sales and Growth Rate (2012-2022)
  1.5.2 United States Musculoskeletal Disorders Drugs Revenue and Growth Rate (2012-2022)

2 UNITED STATES MUSCULOSKELETAL DISORDERS DRUGS MARKET COMPETITION BY PLAYERS/SUPPLIERS

2.1 United States Musculoskeletal Disorders Drugs Sales and Market Share of Key Players/Suppliers (2012-2017)
2.2 United States Musculoskeletal Disorders Drugs Revenue and Share by Players/Suppliers (2012-2017)
2.3 United States Musculoskeletal Disorders Drugs Average Price by Players/Suppliers (2012-2017)
2.4 United States Musculoskeletal Disorders Drugs Market Competitive Situation and Trends
  2.4.1 United States Musculoskeletal Disorders Drugs Market Concentration Rate
  2.4.2 United States Musculoskeletal Disorders Drugs Market Share of Top 3 and Top 5 Players/Suppliers
  2.4.3 Mergers & Acquisitions, Expansion in United States Market
2.5 United States Players/Suppliers Musculoskeletal Disorders Drugs Manufacturing Base Distribution, Sales Area, Product Type

3 UNITED STATES MUSCULOSKELETAL DISORDERS DRUGS SALES (VOLUME) AND REVENUE (VALUE) BY REGION (2012-2017)

3.1 United States Musculoskeletal Disorders Drugs Sales and Market Share by Region (2012-2017)
3.2 United States Musculoskeletal Disorders Drugs Revenue and Market Share by Region (2012-2017)
3.3 United States Musculoskeletal Disorders Drugs Price by Region (2012-2017)

4 UNITED STATES MUSCULOSKELETAL DISORDERS DRUGS SALES (VOLUME) AND REVENUE (VALUE) BY TYPE (PRODUCT CATEGORY) (2012-2017)

4.1 United States Musculoskeletal Disorders Drugs Sales and Market Share by Type (Product Category) (2012-2017)
4.2 United States Musculoskeletal Disorders Drugs Revenue and Market Share by Type (2012-2017)
4.3 United States Musculoskeletal Disorders Drugs Price by Type (2012-2017)
4.4 United States Musculoskeletal Disorders Drugs Sales Growth Rate by Type (2012-2017)

5 UNITED STATES MUSCULOSKELETAL DISORDERS DRUGS SALES (VOLUME) BY APPLICATION (2012-2017)

5.1 United States Musculoskeletal Disorders Drugs Sales and Market Share by Application (2012-2017)
5.2 United States Musculoskeletal Disorders Drugs Sales Growth Rate by Application (2012-2017)
5.3 Market Drivers and Opportunities

6 UNITED STATES MUSCULOSKELETAL DISORDERS DRUGS PLAYERS/SUPPLIERS PROFILES AND SALES DATA

6.1 AbbVie
  6.1.1 Company Basic Information, Manufacturing Base and Competitors
  6.1.2 Musculoskeletal Disorders Drugs Product Category, Application and Specification
    6.1.2.1 Product A
    6.1.2.2 Product B
  6.1.3 AbbVie Musculoskeletal Disorders Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.1.4 Main Business/Business Overview
6.2 Amgen
  6.2.2 Musculoskeletal Disorders Drugs Product Category, Application and Specification
    6.2.2.1 Product A
    6.2.2.2 Product B
  6.2.3 Amgen Musculoskeletal Disorders Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.2.4 Main Business/Business Overview
6.3 Johnson & Johnson
  6.3.2 Musculoskeletal Disorders Drugs Product Category, Application and Specification
    6.3.2.1 Product A
    6.3.2.2 Product B
  6.3.3 Johnson & Johnson Musculoskeletal Disorders Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.3.4 Main Business/Business Overview
6.4 F. Hoffmann-La Roche Ltd
  6.4.2 Musculoskeletal Disorders Drugs Product Category, Application and Specification
    6.4.2.1 Product A
    6.4.2.2 Product B
  6.4.3 F. Hoffmann-La Roche Ltd Musculoskeletal Disorders Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.4.4 Main Business/Business Overview
6.5 Pfizer Inc
  6.5.2 Musculoskeletal Disorders Drugs Product Category, Application and Specification
    6.5.2.1 Product A
    6.5.2.2 Product B
  6.5.3 Pfizer Inc Musculoskeletal Disorders Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.5.4 Main Business/Business Overview
6.6 Eli Lilly
  6.6.2 Musculoskeletal Disorders Drugs Product Category, Application and Specification
    6.6.2.1 Product A
    6.6.2.2 Product B
  6.6.3 Eli Lilly Musculoskeletal Disorders Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.6.4 Main Business/Business Overview

7 MUSCULOSKELETAL DISORDERS DRUGS MANUFACTURING COST ANALYSIS

7.1 Musculoskeletal Disorders Drugs Key Raw Materials Analysis
  7.1.1 Key Raw Materials
  7.1.2 Price Trend of Key Raw Materials
  7.1.3 Key Suppliers of Raw Materials
  7.1.4 Market Concentration Rate of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
  7.2.1 Raw Materials
  7.2.2 Labor Cost
  7.2.3 Manufacturing Expenses
7.3 Manufacturing Process Analysis of Musculoskeletal Disorders Drugs

8 INDUSTRIAL CHAIN, SOURCING STRATEGY AND DOWNSTREAM BUYERS

8.1 Musculoskeletal Disorders Drugs Industrial Chain Analysis
8.2 Upstream Raw Materials Sourcing
8.3 Raw Materials Sources of Musculoskeletal Disorders Drugs Major Manufacturers in 2016
8.4 Downstream Buyers

9 MARKETING STRATEGY ANALYSIS, DISTRIBUTORS/TRADERS

9.1 Marketing Channel
  9.1.1 Direct Marketing
  9.1.2 Indirect Marketing
  9.1.3 Marketing Channel Development Trend
9.2 Market Positioning
  9.2.1 Pricing Strategy
  9.2.2 Brand Strategy
  9.2.3 Target Client
9.3 Distributors/Traders List

10 MARKET EFFECT FACTORS ANALYSIS

10.1 Technology Progress/Risk
  10.1.1 Substitutes Threat
  10.1.2 Technology Progress in Related Industry
10.2 Consumer Needs/Customer Preference Change
10.3 Economic/Political Environmental Change

11 UNITED STATES MUSCULOSKELETAL DISORDERS DRUGS MARKET SIZE (VALUE AND VOLUME) FORECAST (2017-2022)

11.1 United States Musculoskeletal Disorders Drugs Sales Volume, Revenue Forecast (2017-2022)
11.2 United States Musculoskeletal Disorders Drugs Sales Volume Forecast by Type (2017-2022)
11.3 United States Musculoskeletal Disorders Drugs Sales Volume Forecast by Application (2017-2022)
11.4 United States Musculoskeletal Disorders Drugs Sales Volume Forecast by Region (2017-2022)

12 RESEARCH FINDINGS AND CONCLUSION

13 APPENDIX

13.1 Methodology/Research Approach
  13.1.1 Research Programs/Design
  13.1.2 Market Size Estimation
  13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
  13.2.1 Secondary Sources
  13.2.2 Primary Sources
13.3 Disclaimer


The report requires updating with new data and is sent in 2-3 business days after order is placed.

List Of Tables

LIST OF TABLES AND FIGURES

Figure Product Picture of Musculoskeletal Disorders Drugs
Figure United States Musculoskeletal Disorders Drugs Market Size (K Pcs) by Type (2012-2022)
Figure United States Musculoskeletal Disorders Drugs Sales Volume Market Share by Type (Product Category) in 2016
Figure Rheumatoid Arthritis Product Picture
Figure Muscle Relaxants Product Picture
Figure Others Product Picture
Figure United States Musculoskeletal Disorders Drugs Market Size (K Pcs) by Application (2012-2022)
Figure United States Sales Market Share of Musculoskeletal Disorders Drugs by Application in 2016
Figure Rheumatoid Arthritis Examples
Table Key Downstream Customer in Rheumatoid Arthritis
Figure Osteoarthritis Examples
Table Key Downstream Customer in Osteoarthritis
Figure Osteoporosis Examples
Table Key Downstream Customer in Osteoporosis
Figure Psoriatic Arthritis Examples
Table Key Downstream Customer in Psoriatic Arthritis
Figure Ankylosing Spondylitis Examples
Table Key Downstream Customer in Ankylosing Spondylitis
Figure Others Examples
Table Key Downstream Customer in Others
Figure United States Musculoskeletal Disorders Drugs Market Size (Million USD) by Region (2012-2022)
Figure The West Musculoskeletal Disorders Drugs Revenue (Million USD) and Growth Rate (2012-2022)
Figure Southwest Musculoskeletal Disorders Drugs Revenue (Million USD) and Growth Rate (2012-2022)
Figure The Middle Atlantic Musculoskeletal Disorders Drugs Revenue (Million USD) and Growth Rate (2012-2022)
Figure New England Musculoskeletal Disorders Drugs Revenue (Million USD) and Growth Rate (2012-2022)
Figure The South of US Musculoskeletal Disorders Drugs Revenue (Million USD) and Growth Rate (2012-2022)
Figure The Midwest Musculoskeletal Disorders Drugs Revenue (Million USD) and Growth Rate (2012-2022)
Figure United States Musculoskeletal Disorders Drugs Sales (K Pcs) and Growth Rate (2012-2022)
Figure United States Musculoskeletal Disorders Drugs Revenue (Million USD) and Growth Rate (2012-2022)
Figure United States Musculoskeletal Disorders Drugs Market Major Players Product Sales Volume (K Pcs) (2012-2017)
Table United States Musculoskeletal Disorders Drugs Sales (K Pcs) of Key Players/Suppliers (2012-2017)
Table United States Musculoskeletal Disorders Drugs Sales Share by Players/Suppliers (2012-2017)
Figure 2016 United States Musculoskeletal Disorders Drugs Sales Share by Players/Suppliers
Figure 2017 United States Musculoskeletal Disorders Drugs Sales Share by Players/Suppliers
Figure United States Musculoskeletal Disorders Drugs Market Major Players Product Revenue (Million USD) (2012-2017)
Table United States Musculoskeletal Disorders Drugs Revenue (Million USD) by Players/Suppliers (2012-2017)
Table United States Musculoskeletal Disorders Drugs Revenue Share by Players/Suppliers (2012-2017)
Figure 2016 United States Musculoskeletal Disorders Drugs Revenue Share by Players/Suppliers
Figure 2017 United States Musculoskeletal Disorders Drugs Revenue Share by Players/Suppliers
Table United States Market Musculoskeletal Disorders Drugs Average Price (USD/Pcs) of Key Players/Suppliers (2012-2017)
Figure United States Market Musculoskeletal Disorders Drugs Average Price (USD/Pcs) of Key Players/Suppliers in 2016
Figure United States Musculoskeletal Disorders Drugs Market Share of Top 3 Players/Suppliers
Figure United States Musculoskeletal Disorders Drugs Market Share of Top 5 Players/Suppliers
Table United States Players/Suppliers Musculoskeletal Disorders Drugs Manufacturing Base Distribution and Sales Area
Table United States Players/Suppliers Musculoskeletal Disorders Drugs Product Category
Table United States Musculoskeletal Disorders Drugs Sales (K Pcs) by Region (2012-2017)
Table United States Musculoskeletal Disorders Drugs Sales Share by Region (2012-2017)
Figure United States Musculoskeletal Disorders Drugs Sales Share by Region (2012-2017)
Figure United States Musculoskeletal Disorders Drugs Sales Market Share by Region in 2016
Table United States Musculoskeletal Disorders Drugs Revenue (Million USD) and Market Share by Region (2012-2017)
Table United States Musculoskeletal Disorders Drugs Revenue Share by Region (2012-2017)
Figure United States Musculoskeletal Disorders Drugs Revenue Market Share by Region (2012-2017)
Figure United States Musculoskeletal Disorders Drugs Revenue Market Share by Region in 2016
Table United States Musculoskeletal Disorders Drugs Price (USD/Pcs) by Region (2012-2017)
Table United States Musculoskeletal Disorders Drugs Sales (K Pcs) by Type (2012-2017)
Table United States Musculoskeletal Disorders Drugs Sales Share by Type (2012-2017)
Figure United States Musculoskeletal Disorders Drugs Sales Share by Type (2012-2017)
Figure United States Musculoskeletal Disorders Drugs Sales Market Share by Type in 2016
Table United States Musculoskeletal Disorders Drugs Revenue (Million USD) and Market Share by Type (2012-2017)
Table United States Musculoskeletal Disorders Drugs Revenue Share by Type (2012-2017)
Figure Revenue Market Share of Musculoskeletal Disorders Drugs by Type (2012-2017)
Figure Revenue Market Share of Musculoskeletal Disorders Drugs by Type in 2016
Table United States Musculoskeletal Disorders Drugs Price (USD/Pcs) by Types (2012-2017)
Figure United States Musculoskeletal Disorders Drugs Sales Growth Rate by Type (2012-2017)
Table United States Musculoskeletal Disorders Drugs Sales (K Pcs) by Application (2012-2017)
Table United States Musculoskeletal Disorders Drugs Sales Market Share by Application (2012-2017)
Figure United States Musculoskeletal Disorders Drugs Sales Market Share by Application (2012-2017)
Figure United States Musculoskeletal Disorders Drugs Sales Market Share by Application in 2016
Table United States Musculoskeletal Disorders Drugs Sales Growth Rate by Application (2012-2017)
Figure United States Musculoskeletal Disorders Drugs Sales Growth Rate by Application (2012-2017)
Table AbbVie Basic Information List
Table AbbVie Musculoskeletal Disorders Drugs Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)
Figure AbbVie Musculoskeletal Disorders Drugs Sales Growth Rate (2012-2017)
Figure AbbVie Musculoskeletal Disorders Drugs Sales Market Share in United States (2012-2017)
Figure AbbVie Musculoskeletal Disorders Drugs Revenue Market Share in United States (2012-2017)
Table Amgen Basic Information List
Table Amgen Musculoskeletal Disorders Drugs Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)
Figure Amgen Musculoskeletal Disorders Drugs Sales Growth Rate (2012-2017)
Figure Amgen Musculoskeletal Disorders Drugs Sales Market Share in United States (2012-2017)
Figure Amgen Musculoskeletal Disorders Drugs Revenue Market Share in United States (2012-2017)
Table Johnson & Johnson Basic Information List
Table Johnson & Johnson Musculoskeletal Disorders Drugs Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)
Figure Johnson & Johnson Musculoskeletal Disorders Drugs Sales Growth Rate (2012-2017)
Figure Johnson & Johnson Musculoskeletal Disorders Drugs Sales Market Share in United States (2012-2017)
Figure Johnson & Johnson Musculoskeletal Disorders Drugs Revenue Market Share in United States (2012-2017)
Table F. Hoffmann-La Roche Ltd Basic Information List
Table F. Hoffmann-La Roche Ltd Musculoskeletal Disorders Drugs Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)
Figure F. Hoffmann-La Roche Ltd Musculoskeletal Disorders Drugs Sales Growth Rate (2012-2017)
Figure F. Hoffmann-La Roche Ltd Musculoskeletal Disorders Drugs Sales Market Share in United States (2012-2017)
Figure F. Hoffmann-La Roche Ltd Musculoskeletal Disorders Drugs Revenue Market Share in United States (2012-2017)
Table Pfizer Inc Basic Information List
Table Pfizer Inc Musculoskeletal Disorders Drugs Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)
Figure Pfizer Inc Musculoskeletal Disorders Drugs Sales Growth Rate (2012-2017)
Figure Pfizer Inc Musculoskeletal Disorders Drugs Sales Market Share in United States (2012-2017)
Figure Pfizer Inc Musculoskeletal Disorders Drugs Revenue Market Share in United States (2012-2017)
Table Eli Lilly Basic Information List
Table Eli Lilly Musculoskeletal Disorders Drugs Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)
Figure Eli Lilly Musculoskeletal Disorders Drugs Sales Growth Rate (2012-2017)
Figure Eli Lilly Musculoskeletal Disorders Drugs Sales Market Share in United States (2012-2017)
Figure Eli Lilly Musculoskeletal Disorders Drugs Revenue Market Share in United States (2012-2017)
Table Production Base and Market Concentration Rate of Raw Material
Figure Price Trend of Key Raw Materials
Table Key Suppliers of Raw Materials
Figure Manufacturing Cost Structure of Musculoskeletal Disorders Drugs
Figure Manufacturing Process Analysis of Musculoskeletal Disorders Drugs
Figure Musculoskeletal Disorders Drugs Industrial Chain Analysis
Table Raw Materials Sources of Musculoskeletal Disorders Drugs Major Players/Suppliers in 2016
Table Major Buyers of Musculoskeletal Disorders Drugs
Table Distributors/Traders List
Figure United States Musculoskeletal Disorders Drugs Sales Volume (K Pcs) and Growth Rate Forecast (2017-2022)
Figure United States Musculoskeletal Disorders Drugs Revenue (Million USD) and Growth Rate Forecast (2017-2022)
Figure United States Musculoskeletal Disorders Drugs Price (USD/Pcs) Trend Forecast (2017-2022)
Table United States Musculoskeletal Disorders Drugs Sales Volume (K Pcs) Forecast by Type (2017-2022)
Figure United States Musculoskeletal Disorders Drugs Sales Volume (K Pcs) Forecast by Type (2017-2022)
Figure United States Musculoskeletal Disorders Drugs Sales Volume (K Pcs) Forecast by Type in 2022
Table United States Musculoskeletal Disorders Drugs Sales Volume (K Pcs) Forecast by Application (2017-2022)
Figure United States Musculoskeletal Disorders Drugs Sales Volume (K Pcs) Forecast by Application (2017-2022)
Figure United States Musculoskeletal Disorders Drugs Sales Volume (K Pcs) Forecast by Application in 2022
Table United States Musculoskeletal Disorders Drugs Sales Volume (K Pcs) Forecast by Region (2017-2022)
Table United States Musculoskeletal Disorders Drugs Sales Volume Share Forecast by Region (2017-2022)
Figure United States Musculoskeletal Disorders Drugs Sales Volume Share Forecast by Region (2017-2022)
Figure United States Musculoskeletal Disorders Drugs Sales Volume Share Forecast by Region in 2022
Table Research Programs/Design for This Report
Figure Bottom-up and Top-down Approaches for This Report
Figure Data Triangulation
Table Key Data Information from Secondary Sources
Table Key Data Information from Primary Sources